^
    Back
    Association details:
    Biomarker:CD22 overexpression
    Cancer:Melanoma
    Drug:Yervoy (ipilimumab) (CTLA4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    PLoS One
    Title:

    CTLA-4 blockade and interferon-a induce proinflammatory transcriptional changes in the tumor immune landscape that correlate with pathologic response in melanoma

    Published date:
    01/11/2021
    Excerpt:
    Patients with locally/regionally advanced melanoma were treated with neoadjuvant combination immunotherapy with high-dose interferon α-2b (HDI) and ipilimumab in a phase I clinical trial...increased expression of baseline pro-inflammatory genes CCL19, CD3D, CD8A, CD22, LY9, IL12RB1, C1S, C7, AMICA1, TIAM1, TIGIT, THY1 was associated with longer OS (p < 0.05).
    Secondary therapy:
    interferon alfa 2b
    DOI:
    10.1371/journal.pone.0245287